Employees: 51
Size Contineum Therapeutics (CTNM) is a United States Health Care company (Biotechnology) with a market value of $363M, the 2925th largest of 3,085 United States companies the cockpit tracks. Shares closed at $9.24 on 18 Nov 2026.
Performance Over six months the shares fell 31.0%, against -24.5% for the median peer and -2.2% for the United States market (cap-weighted) — 10th lowest of 20 in its peer set.
Short interest Short interest is 10.5% of the free float (30 Oct 2026).
Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $50.0M | $0 |
| Revenue growth | — | — | -100% | — | — |
| Gross profit | -$383,000 | -$323,000 | -$258,000 | $49.8M | -$329,000 |
| EBITDA | -$72.0M | -$67.7M | -$50.6M | $16.3M | -$22.4M |
| Net income | -$63.5M | -$60.0M | -$42.3M | $22.7M | -$24.3M |
| Free cash flow | -$52.0M | -$55.5M | -$33.4M | $18.9M | -$20.2M |
| Capital expenditure | $360,000 | $231,000 | $514,000 | $414,000 | $118,000 |
| Total debt | $6.27M | $8.25M | $6.26M | $193M | $138M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CTNM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.2% | -5.7% | 4th highest of 20 |
| 6-month return | -31.0% | -24.5% | 10th lowest of 20 |
| Distance from 52-week high | -48.0% | -49.8% | 10th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Contineum Therapeutics CTNM | United States | $363M | -31% | n/a | n/a | n/a | n/a | n/a |
| Onconic Therapeutics 476060.KS | South Korea | $368M | -49% | +179% | 21% | 5.2× | 0.6% | +725.2% |
| CorMedix CRMD | United States | $358M | -43% | +92% | 39% | 0.4× | n/a | n/a |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $370M | -31% | 0% | -4% | 2.6× | n/a | n/a |
| Medy-Tox 086900.KS | South Korea | $350M | -36% | +3% | 10% | 2.2× | 4.7% | +11.9% |
| Aspen Neuroscience ASPE | United States | $349M | n/a | n/a | n/a | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $378M | -15% | -4% | -1,617% | 27.4× | n/a | n/a |
| Alector ALEC | United States | $383M | +21% | +151% | 25% | 1.5× | n/a | n/a |
| Lyell Immunopharma LYEL | United States | $341M | -19% | -63% | -1,388,360% | 13,911.5× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $386M | -16% | +6% | -10% | 6.0× | n/a | n/a |
| GI Innovation 358570.KS | South Korea | $339M | -47% | +1,527% | -918% | 78.5× | n/a | n/a |
| Polynovo PNV.AX | Australia | $388M | -34% | +13% | 5% | 3.9× | 51.9% | +37.6% |
| Larimar Therapeutics LRMR | United States | $337M | -9% | n/a | n/a | n/a | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $391M | -20% | +6% | -2% | 1.7× | 36.6% | +8.9% |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $395M | -41% | -30% | -27% | 5.2× | n/a | n/a |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $396M | -33% | n/a | n/a | n/a | n/a | n/a |
| Medtide 3880.HK | Hong Kong | $331M | -17% | +14% | 36% | 2.4× | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $402M | -22% | -17% | -16% | 10.9× | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $326M | -53% | n/a | -57% | 4.7× | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $404M | -24% | +286% | 68% | 1.9× | -18.8% | -36.1% |
| C4 Therapeutics CCCC | United States | $325M | -25% | +7% | -316% | 5.4× | n/a | n/a |